Resonetics to acquire SAES Medical Nitinol Business

Expands nitinol raw material and component manufacturing capabilities to address the industry's growing need for technological advances.

Resonetics to acquire SAES Medical Nitinol Business
Resonetics

Resonetics has signed an agreement to acquire Memry Corporation and SAES Smart Materials Inc. from SAES Getters S.p.A, Milan, Italy. Both acquired businesses are based in the United States with operations in Bethel, Connecticut, New Hartford, New York, and Menlo Park, California. Resonetics is backed by funds managed by global investment firm Carlyle and leading private equity firm GTCR. The transaction is valued at $900 million.

"The SAES Medical Nitinol business is a leading supplier to the medical device industry with a broad set of capabilities focused 100% on nitinol, a novel superelastic, shape-memory alloy that is enabling many technological advances in a growing array of therapeutic areas including structural heart, peripheral vascular, electrophysiology, neurovascular, and orthopaedics," says Tom Burns, president and CEO of Resonetics. "Upon completion of the deal, Resonetics will have the supply and scale to better address the growing customer needs for nitinol material, components, and implants. We will continue to provide a high level of service to all our customers, including contract manufacturers who serve the medical device industry. We look forward to offering customers enhanced options and products as a result of this transaction, and to working with the 550 employees at SAES Medical Nitinol that will be joining our team once the acquisition closes."

"We are excited to support the Resonetics management team as it executes on a high growth strategy to bolster its platform of differentiated capabilities to better serve customers," says Robert Schmidt, a managing director specializing in healthcare at Carlyle. "We believe Resonetics and the SAES Medical Nitinol business are highly complementary to each other and this combination, in our view, will result in an even stronger service offering to large medical technology companies across the world."

"GTCR is eager to invest this additional equity in Resonetics to support the company's continued strong growth and believes the acquisition of the SAES Medical Nitinol business will strengthen Resonetics' portfolio of unique products and services to the medical device community," says Sean Cunningham, managing director and co-head of Healthcare at GTCR. "We look forward to partnering with the SAES Medical Nitinol team through our continued support of the Resonetics business."

Resonetics currently operates nitinol centers of excellence in San Diego, California, and Or Akiva, Israel with a focus on laser cutting, braiding, shape setting, and electropolishing. In addition, Resonetics is a leader in centerless grinding of nitinol wire with operations in Blaine, Minnesota and Alajuela, Costa Rica. The Memry business will add extensive electric discharge machining (EDM) capabilities, as well as additional laser processing, centerless grinding, nitinol tubing, sheet, and wire fabrication. The SAES Smart Materials business creates the nitinol raw material from nickel and titanium raw material and converts it into various form factors.

The transaction is expected to close in 2023, subject to the receipt of required regulatory clearances and approvals and the satisfaction of other closing conditions, including the approval of SAES Getters S.p.A. Board of Directors. Until the transaction closes, each company will continue to operate independently. Mediobanca S.p.A. acted as exclusive financial advisor to Resonetics.

Share This Content